Display options
Cite
Shadambikar G, Marathe S, Ji N, et al. Formulation development of itraconazole PEGylated nano-lipid carriers for pulmonary aspergillosis using hot-melt extrusion technology. Int J Pharm X. 2021;3:100074doi: 10.1016/j.ijpx.2021.100074.
Shadambikar, G., Marathe, S., Ji, N., Almutairi, M., Bandari, S., Zhang, F., Chougule, M., & Repka, M. (2021). Formulation development of itraconazole PEGylated nano-lipid carriers for pulmonary aspergillosis using hot-melt extrusion technology. International journal of pharmaceutics: X, 3100074. https://doi.org/10.1016/j.ijpx.2021.100074
Shadambikar, Gauri, et al. "Formulation development of itraconazole PEGylated nano-lipid carriers for pulmonary aspergillosis using hot-melt extrusion technology." International journal of pharmaceutics: X vol. 3 (2021): 100074. doi: https://doi.org/10.1016/j.ijpx.2021.100074
Shadambikar G, Marathe S, Ji N, Almutairi M, Bandari S, Zhang F, Chougule M, Repka M. Formulation development of itraconazole PEGylated nano-lipid carriers for pulmonary aspergillosis using hot-melt extrusion technology. Int J Pharm X. 2021 Mar 03;3:100074. doi: 10.1016/j.ijpx.2021.100074. eCollection 2021 Dec. PMID: 33748741; PMCID: PMC7973123.
Copy Download .nbib Format: NLM
Share it on

Int J Pharm X. 2021 Mar 03;3:100074. doi: 10.1016/j.ijpx.2021.100074. eCollection 2021 Dec.

Formulation development of itraconazole PEGylated nano-lipid carriers for pulmonary aspergillosis using hot-melt extrusion technology.

International journal of pharmaceutics: X

Gauri Shadambikar, Sushrut Marathe, Nan Ji, Mashan Almutairi, Suresh Bandari, Feng Zhang, Mahavir Chougule, Michael Repka

Affiliations

  1. Department of Pharmaceutics and Drug Delivery, University of Mississippi, University, MS 38677, USA.
  2. Department of Pharmaceutics, College of Pharmacy, University of Hail, Hail 81442, Saudi Arabia.
  3. College of Pharmacy, The University of Texas at Austin, TX 78712, USA.
  4. Pii Center for Pharmaceutical Technology, University of Mississippi, University, MS 38677, USA.

PMID: 33748741 PMCID: PMC7973123 DOI: 10.1016/j.ijpx.2021.100074

Abstract

Pulmonary delivery is a promising alternative for the oral treatment of pulmonary aspergillosis. This study aimed to develop continuous and scalable itraconazole PEGylated nano-lipid carriers (ITZ-PEG-NLC) for inhalation delivery. The feasibility of preparing NLCs utilizing hot-melt extrusion (HME) coupled with probe sonication was investigated. The process parameters for HME and sonication were varied to optimize the formulation. ITZ-PEG-NLC (particle size, 101.20 ± 1.69 nm; polydispersity index, 0.26 ± 0.01) was successfully formulated. The drug entrapment efficiency of ITZ-PEG-NLC was 97.28 ± 0.50%. Transmission electron microscopy was used to characterize the shape of the particles. The developed formulations were evaluated for their aerodynamic properties for pulmonary delivery. The lung deposition of ITZ-PEG-NLC was determined using an Anderson Cascade Impactor and Philips Respironics Sami the Seal Nebulizer Compressor.

© 2021 The Author(s).

Keywords: Hot-melt extrusion; Inhalation; Itraconazole; Nanostructured lipid carriers; PEGylation; Pulmonary drug delivery

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

  1. Int J Pharm. 2010 Jun 15;392(1-2):1-19 - PubMed
  2. J Physiol Pharmacol. 2011 Feb;62(1):45-53 - PubMed
  3. J Pharm Sci. 2011 May;100(5):1892-9 - PubMed
  4. Adv Drug Deliv Rev. 2009 Feb 27;61(2):158-71 - PubMed
  5. Int J Pharm. 2009 Jan 21;366(1-2):170-84 - PubMed
  6. Eur J Pharm Biopharm. 2016 Nov;108:269-276 - PubMed
  7. AAPS J. 2015 Mar;17(2):301-6 - PubMed
  8. Expert Opin Drug Deliv. 2008 Dec;5(12):1357-76 - PubMed
  9. Int J Pharm. 2008 May 22;356(1-2):239-47 - PubMed
  10. Methods Enzymol. 2009;464:167-91 - PubMed
  11. Expert Opin Drug Deliv. 2016;13(3):451-64 - PubMed
  12. Int J Pharm. 2014 Aug 25;471(1-2):153-6 - PubMed
  13. Drug Dev Ind Pharm. 2017 Aug;43(8):1229-1238 - PubMed
  14. Pharm Res. 1995 Nov;12(11):1682-8 - PubMed
  15. AAPS PharmSciTech. 2018 Jan;19(1):12-26 - PubMed
  16. Pharmaceutics. 2020 Oct 24;12(11): - PubMed
  17. AAPS J. 2015 Jan;17(1):194-205 - PubMed
  18. Int J Nanomedicine. 2014 May 02;9:2117-26 - PubMed
  19. Biomaterials. 2009 May;30(13):2591-7 - PubMed
  20. J Control Release. 2010 Jun 1;144(2):233-41 - PubMed
  21. Pharm Res. 2016 Jun;33(6):1456-71 - PubMed
  22. Br J Clin Pharmacol. 2003 Dec;56(6):588-99 - PubMed
  23. Med Mycol. 2009;47 Suppl 1:S291-8 - PubMed
  24. J Infect. 2007 Jul;55(1):68-74 - PubMed
  25. J Phys Chem C Nanomater Interfaces. 2019 Jul 11;123(27):16495-16507 - PubMed
  26. Drug Dev Ind Pharm. 2007 Oct;33(10):1043-57 - PubMed
  27. Int J Pharm. 2011 Sep 20;416(2):461-70 - PubMed
  28. Nanomedicine (Lond). 2013 Jun;8(6):935-49 - PubMed
  29. Eur Respir Rev. 2011 Sep 1;20(121):156-74 - PubMed
  30. J Antimicrob Chemother. 2005 Sep;56 Suppl 1:i33-i38 - PubMed
  31. Int J Pharm. 2011 Oct 31;419(1-2):329-38 - PubMed
  32. Int J Pharm. 2002 Aug 21;242(1-2):121-8 - PubMed
  33. AAPS PharmSciTech. 2021 Jan 14;22(1):48 - PubMed
  34. J Pharm Sci. 2017 Apr;106(4):1085-1091 - PubMed
  35. Biomaterials. 2013 Apr;34(13):3439-46 - PubMed
  36. Expert Opin Drug Deliv. 2019 May;16(5):539-550 - PubMed
  37. Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):28-51 - PubMed
  38. J Control Release. 2003 Jan 9;86(1):131-44 - PubMed
  39. Int J Pharm. 2002 Apr 26;237(1-2):119-28 - PubMed
  40. Eur J Pharm Biopharm. 2003 Jul;56(1):29-36 - PubMed

Publication Types